The country's first messenger mRNA vaccine is expected to begin trials on humans in February.

The Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also completed the recruitment of phase 3 data. Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon, the official sources said.

Gennova Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on…

Pune-based Gennova Biopharmaceuticals Ltd is creating an Omicron-specific Covid-19 vaccine that could be ready in a month or two, said an official.

The manufacturer has nearly completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine; it has started working on Omicron-specific vaccines using the same technology.

The mRNA technology or messenger RNA affects the injection of a small part of the virus' genetic code (RNA) to produce the recipient's immune response. It…

Pune-based pharmaceutical manufacturer Gennova Biopharmaceuticals Ltd has almost completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine even as the company has started developing an Omicron-specific vaccine using the same technology. Gennova has developed an mRNA vaccine for the Omicron variant, which will be tested for safety and efficacy for use in humans.

Messenger RNA or mRNA technology involves the injection of a small part of the virus’s genetic code (RNA) to…

India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in…

The country's first messenger RNA, or mRNA, vaccine, is prepping for launch with the Pune-based Gennova Biopharmaceuticals on course with its human trials, reports say, adding that a variant-specific version is also in the works to tackle the Omicron variant. Amid the pandemic, mRNA vaccines have reported a strong ability to impart protection against the novel coronavirus and two notable candidates – created by Pfizer-BioNTech and Moderna – are the mainstays of the vaccination drive of…

India’s Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

The source, who did not want to be named as the information was private, said the product may need a small trial in India before it can be rolled out as a booster or a stand-alone vaccine.

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that operates in some 70…

Pune-based pharmaceutical manufacturer Gennova Biopharmaceuticals Ltd has almost completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine even as the company has started developing an Omicron-specific vaccine using the same technology. Gennova has developed an mRNA vaccine for the Omicron variant, which will be tested for safety and efficacy for use in humans, a Times of India report said.

Messenger RNA or mRNA technology involves the injection of a small part of the…

India could soon have its first messenger or mRNA vaccine soon have its first messenger or mRNA vaccine soon, with the near-completion of Phase 3 clinical trials by Gennova Biopharmaceuticals, even as the company also started developing a variant or Omicron-specific vaccine using the same tech platform.

The Pune firm has recently submitted Phase 2 trial data of their two-dose mRNA vaccine, and is close to completing phase 3 trials (over 3000 of the 4000 subjects have received the 2nd…

The Indian primary market is expected to remain hectic in the new year, with a bunch of companies such as Adani Wilmar, Global Hospitals (Medanta) and Emcure Pharma likely to launch their initial public offerings (IPOs) in the month of January.

Other companies such as skin care company VLCC, ventilator maker Skanray Technologies, stent maker Sahajanand Medical Technologies, Healthium Medtech, AGS Transact ESDS Software, Traxcn Technologies and CMR Green Technology are also expected to…

NEW DELHI (Reuters) -India's Gennova Biopharmaceuticals is working on an Omicron-specific mRNA COVID-19 vaccine candidate, it told Reuters on Monday, after a person with direct knowledge of the matter said the product could be ready in a month or two.

"The Omicron-specific variant of the vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals," a company spokesperson said in a text message. "We will keep you posted."

Read more at…

Namita Thapar (born 21st March 1977, Age: 44 years) is a businesswoman, entrepreneur, expert advisor, investor, and director of Emcure Pharmaceuticals from India. Her name is enough to introduce her but still, we will do our best to connect you with her complete details.

Read more at https://www.newsunzip.com/wiki/namita-thapar/

Skippi Ice Pops created history becoming the 1st brand on Shark Tank India to receive an 'All Shark Deal'.

Impressed by the pitch and the product, Skippi Icepops received backing from all 5 sharks - Ashneer Grover, MD, and Co-Founder, Bharat Pe, Anupam Mittal, Founder and CEO, Shaddi.com, Aman Gupta, Co-Founder and CMO, boat, Vineeta Singh, CEO and Co-Founder, SUGAR Cosmetics, NamitaThapar, Executive Director and Emcure Pharmaceuticals.

Read more at…

Emcure Pharmaceuticals Ltd (EPL) reported that it received an emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the introduction of Molnupiravir the oral anti-viral that is under investigation, to treat mild COVID-19.

Earlier this year, EPL was able to sign an agreement for licensing with Merck Sharpe Dohme (MSD) to produce and distribute Molnupiravir to India as well as over 100 countries of low and middle-income (LMICs). Molnupiravir is an oral…

Emcure Pharma, Adani Wilmar, GoAir among those lined up; LIC’s mega offer awaited
The IPOs flurry of 2021 is expected to turn into a frenzy in 2022 with the mega LIC offering set to push the overall mop-up via Initial Public Offer to about ₹2-lakh crore this year. This will be significantly higher than the record IPO mop up of ₹1.31-lakh crore by 65 companies in 2021.
Read more at

Emcure Pharmaceuticals to launch oral Covid-19 drug in a week’s time in India

Emcure Pharmaceuticals Limited (EPL) announced that it has received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the launch of Molnupiravir, an investigational oral anti-viral drug, for the treatment of mild COVID-19. EPL plans to launch Molnupiravir under the brand name Lizuvira in the Indian market.

Read more at…

Homegrown Emcure Pharmaceuticals Ltd on Friday announced that it has received Emergency Use Authorization (EUA) approval for the launch of Molnupiravir, an investigational oral anti-viral drug, for the treatment of mild Covid-19. The pharmaceutical company, which has received approval from the Drug Controller General of India, said that it plans to launch Molnupiravir under the brand name Lizuvira in the Indian market. "As the need for such a drug is imminent in the face of emerging…

Emcure Pharmaceuticals Ltd (EPL) on Friday said it will launch its generic version of anti-COVID-19 pill Molnupiravir in a week in India. The company plans to launch Molnupiravir under the brand name 'Lizuvira' in the Indian market, EPL said in a statement.

"As the need for such a drug is imminent in the face of emerging challenges in COVID-19 treatment, EPL will endeavour to deliver Lizuvira (Molnupiravir) in a week's time. A toll-free helpline will be dedicated to help the doctors…

New Delhi, Dec 31 (IANS) Homegrown Emcure Pharmaceuticals Ltd on Friday announced that it has received Emergency Use Authorisation (EUA) approval for the launch of Molnupiravir, an investigational oral anti-viral drug, for the treatment of mild Covid-19.

The pharmaceutical company, which has received approval from the Drug Controller General of India, said that it plans to launch Molnupiravir under the brand name Lizuvira in the Indian market.

Read more at…

At 21, Namita Thapar was a qualified chartered accountant. "I was a bit of a nerd since I cleared it in the first attempt," she laughs. A year later, she was in the US for her MBA, at Duke University's Fuqua School of Business. "The average age of the class was 28 and I was much younger. They still took me," says Thapar. Right after the programme, she spent six years at Guidant Corporation, in finance and marketing. Back home, her father and promoter of Emcure Pharmaceuticals, Satish Mehta,…

Get ready for an exciting meet-and-greet on Kaun Banega Crorepati 13! Ahead of the launch of the very first edition of Shark Tank India, Mr. Bachchan met the ‘Sharks’ on KBC. Who are the ‘Sharks’ you ask? The supremely talented and experienced business investors a.k.a The Sharks – Ashneer Grover (Founder and Managing Director of BharatPe), Vineeta Singh (CEO & Co-founder of SUGAR Cosmetics), Peeyush Bansal (Founder & CEO of Lenskart), Namita Thapar (Executive Director of Emcure…